Brought to you by 
Cellectis SA completes €19.5mm IPO on Alternext
Jan 2007
Executive Summary
A 1999 Institut Pasteur spin-off, Cellectis SA (genome engineering) raised more than the €14.6mm it expected, netting €19.5mm ($25.2mm) in its IPO of 2.1mm shares priced at €10.25 apiece, the high end of the anticipated €8.90-10.25 range. Its stock will trade on the Alternext market of Euronext, Paris.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cellectis SA completes €19.5mm IPO on Alternext
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice